A5000976216- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Immunotherapy and Immune Responses
- Rheumatoid Arthritis Research and Therapies
- Ocular Diseases and Behçet’s Syndrome
- Systemic Lupus Erythematosus Research
- Glaucoma and retinal disorders
- Retinal and Optic Conditions
- Polyomavirus and related diseases
- Cytokine Signaling Pathways and Interactions
- Ophthalmology and Visual Impairment Studies
- SARS-CoV-2 and COVID-19 Research
- Acute Lymphoblastic Leukemia research
- Ultrasound Imaging and Elastography
- Advanced Neuroimaging Techniques and Applications
- Sphingolipid Metabolism and Signaling
- Optical Coherence Tomography Applications
- Herpesvirus Infections and Treatments
- Gout, Hyperuricemia, Uric Acid
- Advanced MRI Techniques and Applications
- Neurogenesis and neuroplasticity mechanisms
- RNA Interference and Gene Delivery
- Amyotrophic Lateral Sclerosis Research
- Neuropeptides and Animal Physiology
- Monoclonal and Polyclonal Antibodies Research
University of Pennsylvania
2012-2024
Hospital of the University of Pennsylvania
2006-2024
New York Medical College
2024
California University of Pennsylvania
2023
University of California, San Francisco
2023
Office of Infectious Diseases
2023
NeuroRx Research (Canada)
2018
Vrije Universiteit Amsterdam
2018
IRCCS Ospedale San Raffaele
2013
Vita-Salute San Raffaele University
2013
Abstract We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with rituximab in patients relapsing‐remitting multiple sclerosis, receiving two courses 6 months apart, followed for a total 72 weeks. No serious adverse events were noted; limited to mild‐to‐moderate infusion‐associated events, which tended decrease subsequent infusions. Infections also mild or moderate, none led withdrawal. Fewer new gadolinium‐enhancing T2 lesions seen starting from week 4...
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune protection against COVID-19. However, little is known about mRNA vaccine-induced responses immunosuppressed patients. We investigated induction of antigen-specific antibody, B cell and T longitudinally patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy (n = 20) compared controls 10) after BNT162b2 or mRNA-1273 vaccination. Treatment monoclonal (aCD20) significantly reduced spike-specific...
Cross-sectional studies of optical coherence tomography (OCT) show that retinal nerve fiber layer (RNFL) thickness is reduced in multiple sclerosis (MS) and correlates with visual function. We determined how longitudinal changes RNFL relate to loss. also examined patterns thinning over time MS eyes without a prior history acute optic neuritis (ON).Patients underwent OCT measurement at baseline 6-month intervals during mean follow-up 18 months 3 centers. Low-contrast letter acuity (2.5%,...
<h3>Background</h3> Inner (area adjacent to the fovea) and outer regions of macula differ with respect relative thicknesses ganglion cell layer (neurons) vs retinal nerve fiber (RNFL; axons). <h3>Objective</h3> To determine how inner macular volumes relate peripapillary RNFL thickness visual function in multiple sclerosis (MS) examine these patterns among eyes without a history acute optic neuritis (ON). <h3>Design</h3> Study using cross-sectional optical coherence tomography....
<b><i>Background:</i></b> Visual dysfunction is one of the most common causes disability in multiple sclerosis (MS). The Multiple Sclerosis Functional Composite (MSFC), a new clinical trial outcome measure, does not currently include test visual function. <b><i>Objective:</i></b> To examine contrast letter acuity as candidate function for MSFC. <b><i>Methods:</i></b> Binocular testing (Sloan charts) was performed subgroup participants from International Secondary Progressive Avonex...
<h3>Objective:</h3> To examine the relation between low contrast letter acuity, a new visual function test for multiple sclerosis (MS) trials, and vision targeted health related quality of life (HRQOL). <h3>Methods:</h3> Patients in this cross sectional study were part an ongoing investigation MS. tested binocularly using acuity Early Treatment Diabetic Retinopathy Study (ETDRS) (VA) charts. The 25 Item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25), 10 Neuro-Ophthalmic...
<h3>Background</h3> Optical coherence tomography (OCT) and scanning laser polarimetry with variable corneal compensation (GDx) are similar yet provide information on different aspects of retinal nerve fiber layer (RNFL) structure (thickness values to histology for OCT vs birefringence microtubules GDx). <h3>Objectives</h3> To compare the ability GDx distinguish eyes patients multiple sclerosis (MS) from disease-free controls thus identify RNFL abnormalities. We also sought examine capacity...
The objective of this study is to evaluate the safety and tolerability inosine in patients with relapsing-remitting multiple sclerosis (RRMS). secondary objectives are assess effects administration on serum urate (UA) levels, progression neurologic disability, cumulative number new, active lesions magnetic resonance imaging (MRI), changes levels for markers inflammation.Oral was used raise natural peroxynitrite scavenger UA 16 RRMS during a 1-year randomized, double-blind trial.The endpoints...
<h3>Objective:</h3> To characterize effects of alemtuzumab treatment on measures disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) inadequate response (≥1 relapse) to prior therapy. <h3>Methods:</h3> Comparison Alemtuzumab and Rebif Efficacy Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy safety 12 mg subcutaneous interferon-β-1a (SC IFN-β-1a) 44 μg RRMS. Prespecified...
Background: Upper extremity (UE) impairment is common with primary progressive multiple sclerosis (PPMS). Objective: This exploratory analysis examined the effects of ocrelizumab on confirmed progression (CP) and improvement (CI) in UE patients from ORATORIO. Methods: Patients PPMS received 600 mg or placebo every 24 weeks for ⩾120 weeks. The Nine-Hole Peg Test (9HPT) was administered at baseline (BL) 12 thereafter. Prespecified endpoints included change 9HPT time proportion CP ⩾20% 9HPT....
Abstract SARS-CoV-2 mRNA vaccination in healthy individuals generates effective immune protection against COVID-19. Little is known, however, about the vaccine-induced responses immunosuppressed patients. We investigated induction of antigen-specific antibody, B cell and T patients with multiple sclerosis on anti-CD20 (MS-aCD20) monotherapy following vaccination. Treatment aCD20 significantly reduced Spike RBD specific antibody memory most patients, an effect that was ameliorated longer...
Multiple sclerosis (MS) is an immune-mediated neurological disorder, and up to 50% of patients experience depression. We investigated how white matter network disruption related depression in MS.
<b>Objective: </b> To examine the relation between low-contrast letter acuity, an emerging visual outcome for multiple sclerosis (MS) clinical trials, and brain MRI abnormalities in MS cohort. <b>Methods: T2 lesion volume parenchymal fraction were determined whole within pathway regions of interest. Magnetization transfer ratio histograms examined. Vision testing was performed binocularly using acuity (2.5%, 1.25% contrast) high-contrast (VA). Linear regression, accounting age disease...
A 36-year-old woman presented with severe dysarthria, axial and appendicular tremor, ataxia.Symptoms began the tremor 2 years prior to presentation.Neurologic examination revealed presence of Kayser-Fleischer rings (figure, A), dysarthria dysphonia, akathisia, truncal left hemiparesis, dystonia.Serum ceruloplasmin was markedly decreased at 10 mg/dL (normal 18 55 mg/dL).An MRI diffuse white matter abnormalities bilateral symmetric involvement midbrain, pons, inferior cerebellum, thalami,...